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Summary 
Background  
Up to 50% of acute stroke patients are taking blood pressure (BP) lowering therapy on 
hospital admission. It is unclear whether such therapy should be continued during the 
immediate post-stroke period. 
 
Methods 
Patients already taking BP-lowering therapy, within 48 hours of both acute stroke and last 
dose of BP-lowering medication, were randomised to continue or stop pre-existing 
medication for two weeks. Primary endpoint was 2-week death or dependency analysed by 
intention-to-treat. This trial is registered with the International Standard Randomised 
Controlled Trial Register, number ISRCTN89712435. 
 
Findings 
763 patients (mean age 74 [SD 11] years; systolic BP [SBP] 150 [SD 22] mmHg; diastolic BP 
[DBP] 81 [SD 13] mmHg; median National Institutes of Health Stroke Scale score 4 [IQR 2-7] 
points) were assigned to continue (n=379) or stop (n=384) pre-existing BP-lowering therapy. 
Death or dependency (Modified Rankin Score >3) at 2 weeks – occurred in 19% (72) of the 
continue and 21% (82) of the stop group (relative risk 0.86, 95% CI 0.65-1.14; p=0.3). BP was 
lower (p<0.0001) at 2 weeks in the continue compared to stop group: SBP 13 mmHg (95% CI 
(10, 17)), DBP 8 mmHg (95% CI (6, 10)). No significant differences were observed between 
groups in serious adverse event rates, 6-month mortality or major cardiovascular events.  
 
Interpretation 
Significantly lower BP levels, in those who continued BP-lowering therapy following acute 
mild stroke, were not associated with an increase in adverse events, but did not reduce 2-
week death or dependency, cardiovascular event rate or mortality at 6 months. These 
neutral results may reflect lack of power since COSSACS was terminated prematurely. 
 
Funding 
The Health Foundation, formerly The PPP Foundation (1459/ 1558) 
The Stroke Association (TSA 02/ 03) 
 
Introduction 
Raised blood pressure (BP) levels are common following acute stroke with more than three-
quarters of patients having a systolic BP (SBP) greater than 140 mmHg on admission [1,2]. 
These elevated levels are associated with a poor prognosis [3,4]; possible underlying 
pathophysiological mechanisms include raised intracranial pressure [5], increased 
sympathetic nervous system activity [6], abnormal baroreceptor sensitivity [7] and 
haematoma expansion [8]. The natural history is for a spontaneous BP fall over 4 to 10 days 
post-ictus [9], but significant BP reductions may be associated with cerebral hypoperfusion 
as a consequence of post-stroke cerebral dysautoregulation [10]. Indeed, data from the 
International Stroke Trial indicate a U-shaped relationship between baseline SBP (within 48 
hours of ictus) and short- (14-day mortality) and long-term (6-month death and 
dependency) outcomes, with an increased risk of early death by 3.6% and late death and 
dependency by 17.9% for every 10 mmHg below 150 mmHg, and an increased risk of early 
death by 3.8% and a non-significant rise in late death and dependency for every 10 mmHg 
above 150 mmHg; the lowest risk corresponding to a SBP of 150 mmHg [11]. 
 
Preliminary data from recent randomised controlled trials suggest that BP can be safely 
reduced following acute stroke [12-15], and may be associated with improved long-term 
mortality [14] and reduced recurrent vascular events [12]. However, the optimal 
management of BP after acute stroke remains uncertain, as evident in recent Cochrane 
meta-analyses [16,17], and highlighted in a number of international acute stroke 
management guidelines [18-22]. Importantly, hypertension is a major modifiable risk factor 
for stroke prevention, and more than 50% of patients are already taking BP-lowering 
therapy at the time of their admission for acute stroke. It is therefore a common clinical 
dilemma as to whether to continue or stop such treatment in the acute stages following 
stroke.  
 
The Continue Or Stop post-Stroke Antihypertensives Collaborative Study (COSSACS) 
assessed the efficacy and safety of continuing or stopping pre-existing BP-lowering therapy 
in a United Kingdom multi-centre, prospective, randomised, open, blinded-endpoint trial of 
non-dysphagic, ischaemic and haemorrhagic stroke patients within 48 hours of ictus and 
within 48 hours of the last dose of BP-lowering therapy. 
 
Methods 
Patients 
Full details of this trial are described elsewhere [23]. Patients were recruited at 49 United 
Kingdom National Institute of Health Research Stroke Research Network centres (Appendix) 
from 1 January 2003 to 31 March 2009. Patients were eligible if they were older than 18 
years and had a clinical diagnosis of acute stroke. Time of stroke onset required clear 
definition; in patients who woke with a suspected stroke, the time of onset was taken as the 
last time the patient was known to be asymptomatic. Inclusion criteria were cerebral 
infarction (but not undergoing thrombolytic treatment) or primary intracerebral 
haemorrhage (PICH), symptom onset within 48 hours, and currently taking BP-lowering 
therapy with the last dose having been taken within 48 hours of randomisation. Exclusion 
criteria included hypertensive encephalopathy, co-existing cardiac or vascular urgency, SBP 
greater than 200mmHg and/ or diastolic (DBP) greater than 120mmHg in association with 
known PICH, contraindications to stopping or indications for continuing BP lowering 
therapy, dysphagia, impaired level of consciousness (National Institutes of Health stroke 
scale (NIHSS) section 1a score >2 points), females of childbearing potential, premorbid 
dependency (modified Rankin score (mRS) >3 points), any co-existing life threatening 
condition with an estimated life expectancy of less than 6 months, and diagnosis of non-
stroke on subsequent neuroimaging. To increase recruitment, amendments were made to 
the original protocol that included an increase in the time from stroke onset to 
randomisation from 24 to 48 hours, an increase in the time from last dose of BP lowering 
therapy to randomisation from 36 to 48 hours, and the inclusion of patients with a pre-
stroke mRS score of 3 points instead of the original 0 to 2 points. These amendments were 
made by the trial steering committee. Informed patient consent (written where possible), 
assent from a relative (with subsequent confirmation of assent by patient when able), or 
assent from an independent clinician was obtained for all patients. The study and 
amendments were approved by the Trent Research Ethics Committee (MREC/02/4/051). 
 
Randomisation and masking 
Patients were randomly assigned by secure internet central randomisation (with a block size 
of 4). Allocation (1:1) to continue or stop pre-existing BP-lowering therapy for a 2-week 
period was done by use of a computer with stratification by the following category: age at 
entry (<75, and >75 years). Patients and randomising clinicians were unmasked to treatment 
allocation. Two-week outcomes were undertaken by a clinician masked to treatment 
allocation; the secure internet data collection facility not allowing 2-week data entry by a 
clinician that had undertaken either randomisation or baseline data entry. Six-month 
outcomes were undertaken by the trial co-ordinating centre, masked to treatment 
allocation. 
 
Procedures 
All other routine aspects of the management of patients, including neuroimaging, acute 
treatment and standard secondary prevention therapy were managed at the discretion of 
the local investigator. BP-lowering therapy following the 2-week study period was at the 
discretion of the local investigator. Baseline assessments included NIHSS, Oxfordshire 
Community Stroke Project (OCSP) classification, mRS and Barthel Index (BI). Casual BP was 
taken as the mean of two sets of three supine brachial BP readings 10 minutes apart, using 
an A&D UA-767 BP monitor in all centres.  In addition, casual BP was monitored throughout 
the treatment period, and patients with symptomatic sustained hypotension (SBP 
<100mmHg), or at the discretion of the treating clinician, were withdrawn from the study. 
 
Study assessments, NIHSS, mRS, BI and casual BP using a validated BP monitor (A&D UA-
767) were repeated at 2 weeks by a researcher blinded to the patient’s randomisation 
status. Long-term follow-up at 6 months was undertaken by the trial co-ordinating centre 
and a researcher blinded to the patient’s randomisation status. Death was noted from the 
NHS Register. Those patients still alive were contacted by telephone, and the International 
Stroke Trial [24] and EuroQoL [25] questionnaires administered to the patient or proxy. In 
addition, current residence and treatment (including BP-lowering therapy) were recorded. 
 All serious adverse events reported during the 2-week treatment period were categorised as 
mild, moderate, severe or fatal. Causality was recorded in terms of whether it was related to 
the treatment (definite, uncertain, or no causality) and the system affected by the local 
investigator. Serious adverse events were reviewed by the trial steering and independent 
data safety monitoring committees at 6-monthly intervals. 
 
The primary endpoint of the trial was death or dependency at 2 weeks, with dependency 
defined as a mRS score of greater than 3 points. The early secondary outcome measures at 2 
weeks included neurological and functional status, casual BP changes between admission 
and 2 weeks, discharge destination and serious adverse events. The late secondary outcome 
measures at 6 months included mortality, fatal and non-fatal stroke recurrence, health-
related quality of life, and place of residence. 
 
This trial is registered with the International Standard Randomised Controlled Trial Register, 
number ISRCTN89712435. 
 
 
Statistical analysis 
Continuous measures, including age, SBP, DBP, haemoglobin, platelets, potassium, total 
cholesterol and ECG heart rate, were approximately normally distributed. Linear regression 
was used to compare 2-week BPs by treatment group. BI, NIHSS, alcohol consumption, 
white cell count, sodium, urea, creatinine, glucose, time since stroke onset and time since 
the last BP-lowering therapy was taken had skewed distributions. Non-parametric Kruskal-
Wallis tests were used to compare 2-week NIHSS and BI by treatment group. For the 
primary outcome (death and dependency at 2 weeks), chi-squared test was performed to 
test the difference between the groups and the difference reported as a risk ratio; logistic 
regression was used when adjustment was needed with results presented as odds ratios. It 
was estimated that 2900 trial participants would be required for a 10%  reduction (absolute 
risk reduction of 6%) in death and dependency between the continue and stop groups at 2 
weeks to be detected, with 90% power at the 5% significance level, assuming an overall rate 
of death and dependency of 60% at 2 weeks [23]. Multinomial logistic regression was used 
to assess whether treatment effect differed across baseline mRS categories. Post-hoc 
analysis was undertaken in the CT-confirmed ischaemic stroke subgroup. Deaths up to 6 
months post-randomisation were recorded from the NHS register, cause of death being 
taken from the death certificates. Major cardiovascular events at 6 months were analysed 
along with the mortality data by chi-squared tests. Survival data were analysed by a non-
parametric log-rank test with a Kaplan-Meier plot.  All analyses were made on an intention-
to-treat basis using Stata version 9.2 statistical software. 
 
Role of the funding source 
The sponsor (University Hospitals of Leicester NHS Trust) and funders (The Health 
Foundation, The Stroke Association) had no role in the study design, data collection, data 
analysis, data interpretation, or the writing of this report. The corresponding author had full 
access to all the data in the study and had final responsibility for the decision to submit for 
publication. 
 
Results 
COSSACS started on 1 January 2003 and ended on 31 March 2009, but was terminated 
before target recruitment was reached (due to slow recruitment and lack of continued 
funding) when 763 patients (56% male), of mean age 74 years (11), with baseline BP 150 
(22)/ 81 (13) mmHg) had been randomised within a median (IQR) of 23.6 (17.9, 34.8) hours 
following stroke onset and 16.0 (6.8, 28.9) hours following last dose of BP-lowering therapy, 
and included in the intention-to-treat analysis (Figure 1). Patients underwent neuroimaging 
to exclude non-stroke diagnoses within a median of 1 (IQR: 1 to 2) days from stroke onset 
(65% undergoing neuroimaging before or on the day of randomisation); 454 (63%) showed 
acute infarction, 9 (1%) haemorrhagic transformation of acute infarction, 38 (5%) primary 
intracerebral haemorrhage, 207 (29%) non-relevant change, and 18 (3%) non-stroke 
diagnosis. At randomisation, the continue and stop groups were well matched for measured 
baseline variables (Table 1), with respect to number of baseline antihypertensive therapy 
(Table 1), classes of antihypertensive, antithrombotic, and cholesterol lowering therapy 
(data not shown), and routine baseline investigations, including haematology, biochemistry 
and electrocardiography (data not shown).  
 
The per protocol population numbered 743 patients; twenty patients being withdrawn post-
randomisation, in 18 cases due to non-stroke diagnosis (Continue – complex regional pain 
syndrome 1, epilepsy 1, meningitis 1, non-organic syndrome 1, secondary tumour 3, not 
specified 1; Stop – Bell’s palsy 1, mononeuritis multiplex 1, primary tumour 2, secondary 
tumour 2, subdural haematoma 1, transient ischaemic attack 1, viral labyrinthitis 1, not 
specified 1), and in 2 cases due to protocol violation (Stop - >48 hours following last BP 
lowering dose 1, contraindication to stop BP lowering treatment 1) (Figure 1). 706 patients 
(92.5%) completed the full 2-week study protocol: 18 cases due to withdrawal of consent/ 
lack of confirmation of relative or independent clinician assent (Continue 8, Stop 10), , 6 
cases by the local investigator (Stop - BP high and requiring treatment 3, acute myocardial 
infarction 1, recurrent ischaemic stroke 1, non-compliant with trial treatment arm 1), and13 
patients lost to 2-week follow-up (Continue 7, Stop 6) (Figure 1).  
 
Primary Endpoint 
The primary outcome of death or dependency (mRS>3) at 2 weeks occurred in 19% (72 
patients) in the continue group and 21% (82 patients) in the stop group (Figure 2, relative 
risk [RR] 0.86, 95% CI 0.65-1.14; p=0.3).  There was no evidence that the treatment effect 
(continue or stop pre-existing BP lowering therapy) differed across 2-week mRS categories 
(p=0.47). In the treatment adjusted model, age (75 years old+, N=391 (51%)) was 
significantly associated with poorer outcome (Odds Ratio [OR] 1.78, 95% CI (1.24, 2.57), 
p=0.002). When adjusted further for smoking, alcohol, gender, neuroimaging evidence of 
acute stroke, history of diabetes, stroke and atrial fibrillation the effect of age remained 
significant (OR 1.76, 95%CI (1.11, 2.81), p=0.017). No interaction effect was found between 
age and treatment group. Neither baseline SBP nor baseline DBP was found to be 
significantly correlated with the primary outcome.  
BP Difference Between Groups 
At 2 weeks, mean BP in the continue group was 140 (22)/ 76 (14)mmHg and in the stop 
group was 153 (24)/ 84 (14)mmHg (Table 2), representing a change of -9 (23)/ -4 (14) and 3 
(25)/ 2 (14)mmHg, respectively, compared to baseline. SBP and DBP were significantly 
(p<0.0001) lower at 2 weeks in the continue compared to the stop arm with a difference of 
13 mmHg (95% CI 10, 17) and 8 (95% CI 6, 10), respectively. Daily BP readings based on 
routine ward recordings are not reported. 
 
Other Secondary Endpoints 
At 2 weeks, there were 4 deaths in the continue group (unknown alive/ dead status in 3) 
and 7 deaths in the stop group (unknown alive/ dead status in 16). There were no significant 
differences in early (2-week) secondary neurological (NIHSS) and functional (BI) outcomes 
between continue and stop arms  (Table 2). At 2 weeks, 158 patients (42%) remained 
hospital in-patients in the continue group compared to 147 patients (38%) in the stop group. 
 
By 6 months, 32 patients in the continue group and 29 patients in the stop group had died, 
providing an overall 6-month mortality of 8.0% (n=61) in both groups (Continue: stroke 5, 
respiratory 4, cardiovascular 2, pulmonary embolism 1, neoplastic 1, sepsis 1, unknown 18; 
Stop: stroke 4, pulmonary embolism 2, neoplastic 2, infection 1, unknown 20) (Table 3, 
Figure 3). In addition, functional outcome was derived from the International Stroke Trial 
telephone-administered questionnaire (Table 3). No differences were found in self-reported 
major cardiovascular event rates at 6 months: recurrent stroke (Continue: 12 vs. Stop: 12), 
cardiovascular (11 vs. 8), and other vascular (3 vs. 4). 
 
In a post-hoc analysis of 444 patients with a definite neuroimaging diagnosis of acute 
ischaemic (including haemorrhagic transformation) stroke and complete 2-week outcome 
data, fewer patients were dead or dependent (mRS>3) at 2 weeks in the continue compared 
to stop group, 46 (19.1%) vs. 55 (27.1%), respectively, with a relative risk reduction of 0.70 
(95% CI: 0.51 to 0.99, p=0.045). The OCSP classification for these patients was: TACS (11%), 
PACS (42%), LACS (35%), POCS (12%). No significant differences were observed in baseline 
data between these groups. For those patients without neuroimaging-confirmed acute 
ischaemic or haemorrhagic stroke diagnosis (i.e. non-relevant change), the OCSP 
classification was: TACS (7%), PACS (40%), LACS (45%), POCS (8%), with a relative risk 
reduction of 1.1 (95% CI: 0.6 to 2.1, p=0.76).  
 
Adverse Events 
96 serious adverse events were reported in 76 patients with 20 patients having more than 
one event, and treatment being discontinued in 32 patients (16 patients in each group). 
Four fatal adverse events were reported in the continue group (stroke 3, pulmonary 
embolism 1), and seven in the stop group (stroke 4, pulmonary embolism 1, infection 1, 
neoplastic 1). 
 
 Discussion 
In this prospective, randomised, open, blinded-endpoint study, continuing compared to 
stopping pre-existing BP-lowering therapy was associated with a significantly lower BP over 
the first 2 weeks. This strategy demonstrated no evidence of increased serious adverse 
events or neurological deterioration, but was not associated with a significant reduction in 
2-week death and dependency. However, due to study closure before target recruitment 
had been achieved owing to lack of further funding, the trial only had 9% power at the 5% 
level to detect a difference of 10% in death and dependency. Nonetheless, the finding in this 
largest acute stroke BP trial to report to date that continuing existing BP-lowering therapy 
following acute stroke shows no evidence of harm is consistent with recently reported 
intervention trials, which suggest that early BP reduction does not result in adverse effects.  
The Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) addressed 
a 36-hour time window [14], and the Acute Candesartan Cilexetil Therapy in Stroke 
Survivors (ACCESS) [12] and a posthoc analysis of the Prevention Regimen for Effectively 
Avoiding Second Strokes (PRoFESS) [15] addressed a 72-hour window from acute ischaemic 
(ACCESS, CHHIPS, PRoFESS) and haemorrhagic (CHHIPS) stroke onset. However, to date, this 
treatment approach has not been associated with significant benefit in early outcome at 1 
(ACCESS) or 2 weeks (CHHIPS), or 30 days (PRoFESS). It was not considered appropriate to 
undertake a meta-analysis of these trials, as COSSACS addressed the issue of continuing or 
stopping pre-existing BP-lowering therapy, whereas the other trials were concerned with 
the introduction of denovo BP-lowering therapy.  
 
Though CHHIPS and ACCESS suggested later benefits with reduced 3-month mortality and 
12-month recurrent vascular events, respectively, this was not seen in either COSSACS (6 
months) or PRoFESS (3 months). In the case of COSSACS, there was insufficient power to 
detect important benefits. Had there been sufficient trial participants, a 9 mmHg SBP 
difference between the continue and stop arms might be expected to be associated with 
significant benefit as reported in a recent meta-regression; SBP reduction of 8 mmHg was 
associated with an odds ratio of 0.87 (95% CI: 0.54-1.23) for early death, and of 14 mmHg 
for an odds ratio of end-of-trial death and dependency of 0.95 (95% CI: 0.11-1.72) [26]. 
However, baseline SBP in the COSSACS population was identical to the lowest risk level 
reported in the U-shaped relationship between SBP and outcome in the International Stroke 
Trial, and may explain why further BP reduction was not beneficial [11]. 
 
To date, the majority of trials have recruited patients relatively late within the post-acute 
stroke time window; COSSACS recruiting a median of 24 hours after stroke onset. Only the 
Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT) 
recruited within a hyperacute time frame, up to 6 hours; demonstrating a significant 
reduction in haematoma expansion with intensive compared to routine BP-lowering therapy 
[13]. It is likely that short-term benefit (or harm) is more likely to be realised with 
hyperacute BP-lowering treatment, and the current evidence base is not sufficient to 
comment on this reliably. However, current results do suggest that BP-lowering treatment 
introduced acutely may have early secondary prevention benefits. 
 
All patients in COSSACS had a clinical diagnosis of stroke confirmed from clinical history and/ 
or neuroimaging, predominantly CT. Consistent with other studies, two-thirds of patients 
with ischaemic stroke had signs of acute ischaemia on CT imaging, and a post-hoc analysis 
was undertaken for this group only. As previously presented, fewer patients with 
neuroimaging-confirmed acute ischaemic stroke were dead or dependent (mRS>3) at 2 
weeks in the continue compared to stop group, 46 (19.1%) vs. 55 (27.1%), respectively, with 
a relative risk reduction of 0.70 (95% CI: 0.51 to 0.99, p=0.045). This may be a chance 
finding, but one explanation for the positive treatment effect in this group of patients is that 
patients with acute stroke due to large vessel disease, who would mostly have positive CT 
brain imaging, may respond differently to BP-lowering therapy compared to patients with 
small vessel disease. However, this finding does suggest that future trials of BP-lowering in 
acute stroke should phenotype stroke subtype with more detailed assessment. 
 
It is possible that the implications of BP-lowering may be different in primary haemorrhage 
and larger infarcts, particularly with co-existent large vessel stenosis or occlusion. Certainly, 
the detrimental effects of hypertension-associated haematoma expansion [8] and cerebral 
oedema [5] may be reduced by BP lowering. However, cerebral hypoperfusion secondary to 
BP reduction in the presence of impaired cerebrovascular autoregulation may be more 
detrimental in association with a larger infarct, increased penumbral zone and poor 
collateral circulation [10]. Indeed, there was a trend for BP reductions associated with 
magnesium in the Intravenous Magnesium Efficacy in Stroke trial (IMAGES) to be associated 
with poorer outcome in patients with cortical syndromes [27]. However, this was also a 
neutral trial, with a positive post-hoc analysis, and it is perhaps not surprising that the 
interpretation is different. Furthermore, it is possible that different antihypertensive classes 
may have differential effects on cerebral blood flow (CBF) [28], for example BP lowering in 
acute stroke associated with beta- and calcium channel blockade may be detrimental [17], 
though small numbers in the present study prevent meaningful comparison between 
antihypertensive classes. However, similar BP-lowering effects and no differences in safety 
were observed using different routes of administration in dysphagic and non-dysphagic 
patients with angiotensin converting enzyme inhibitors and beta-blockers in the CHHIPS 
Trial, though formal assessment of CBF was not made [14]. 
 
There a number of limitations with the COSSACS trial. Firstly, Iit was necessary to exclude 
dysphagic patients from COSSACS. It is common practice to administer BP-lowering therapy 
by crushing tablets or administering as a suspension, either orally or by nasogastric tube, to 
dysphagic patients. However, , because regulatory approval for COSSACS required 
medication to be administered by its licensed route and format. Furthermore, BP-lowering 
therapy can be administered by non-oral routes, and this has been examined in previous 
studies [17]. Secondly, Therefore, COSSACS is a trial of continuing or stopping pre-existing 
BP-lowering therapy in a mild stroke population (median NIHSS score 4), with few 
haemorrhagic stroke patients (5%). In keeping with this, a 2-week death and dependency 
rate of only 19% and 21% was reported in the continue and stop groups, respectively, 
though this may also reflect an increased application of evidence-based stroke care, 
including stroke units, in the United Kingdom [29]. Therefore, COSSACS does not provide 
information in respect of benefit or harm for a strategy of continuing or stopping pre-
existing BP-lowering therapy in moderate or severe stroke patients, and it is important that 
ongoing trials consider this population. Thirdly, it is known that the risk of recurrent 
disabling stroke is front-loaded after minor stroke [30], but that previous studies have 
indicated potential benefit associated with early BP-lowering interventions at 3 months 
(CHHIPS) [14] and 12 months (ACCESS) [12]. Therefore, end-points at 2 weeks and 6 months, 
rather than the commonly used 3-month end-point, were used to capture early safety and 
later secondary prevention benefit outcomes.  
 
As previously discussed, a further limitation was that the median time to recruitment 
following stroke onset was 24 hours. Though comparable with a previously completed trial, 
ACCESS [12], this does not inform the risks and benefits of hyperacute BP lowering. 
Furthermore, diagnostic confirmation by neuroimaging was only available in 65% of patients 
before on the day of randomisation, though pre-randomisation neuroimaging is ideally a 
prerequisite for acute stroke trials and increasingly deliverable with more recent United 
Kingdom stroke service developments. Finally, dependency was defined by a Modified 
Rankin Score of 4 or 5, excluding a score of 3, as patients were included with this level of 
dependency following a protocol amendment to enhance recruitment, accounting for 
approximately 4% of trial participants, and reflecting that acute stroke patients often have 
premorbid disability. A further limitation of the trial relates to the missing 2-week and 6-
month outcome data.  
 
Given the observed death and dependency rate of 21% in the COSSACS stop arm, a study of 
15,406 patients would have been required to demonstrate a relative reduction in the 
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primary outcome of 10% at a 90% power at a 2-sided α-level of 5%. Therefore, COSSACS is 
significantly underpowered to address the efficacy of continuing or stopping BP-lowering 
therapy following acute stroke, and was terminated because of a lack of continued funding. 
It also reflects the difficulty in recruiting to trials where patients consent to potentially stop 
their pre-existing BP-lowering therapy [310]. Nonetheless, these results support the 
continuation of ongoing trials to assess the introduction of de novo treatment in acute 
stroke hypertension (Efficacy in Nitric Oxide (Efficacy of Nitric Oxide in Stroke (ENOS) trial) 
[312], Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial 
(INTERACT2), Scandinavian Candesartan Acute Stroke Trial (SCAST)), and whether to 
continue or stop pre-existing therapy (ENOS). In particular, larger numbers of patients are 
required to address the importance of a number of factors for the efficacy of BP reduction in 
acute stroke, including: stroke type (ischaemic vs. haemorrhagic), aetiology (large vs. small 
vessel), site (cortical vs. subcortical), antihypertensive class, duration of treatment, and 
degree of BP reduction. In addition, these trials must address hyperacute BP lowering, as 
COSSACS and other trials have suggested that this strategy appears safe in the subacute 
period. 
 
In conclusion, in COSSACS, there was no obvious signal of harm associated with a strategy of 
continuing compared to stopping pre-existing BP-lowering therapy within 48 hours of acute 
ischaemic or haemorrhagic stroke onset and within 48 hours of last dose of BP-lowering 
therapy for a 2-week period. It is possible that continuing BP-lowering therapy is associated 
with reduced 2-week death and dependency, particularly in confirmed ischaemic stroke 
patients. However, this post-hoc subgroup analysis requires further evaluation in patient 
populations with well-defined stroke subtype, and ongoing trials need to address this and 
other important questions in the management of this common clinical dilemma. 
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Figure 1: Trial Protocol 
763 randomly assigned 
Continue Stop 
379 ITT Population 384 ITT Population 
8 Non-stroke diagnosis 10 non-stroke diagnosis 
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10 consent withdrawn 
3  withdrawn high BP 
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7 lost to follow-up 
356 Completed 2 week 
 study period 
350 Completed 2 week 
 study period 
MI: myocardial infarction, IS: ischaemic stroke, Rx: treatment. 
 
Table 1: Baseline characteristics of the COSSACS patients at randomisation (Intention To 
Treat Population) 
 Continue 
(n=379) 
Stop 
(n=384) 
Gender, n (%) 
     Male    
 
210 (56) 
 
216 (57) 
Age in years, mean (SD) 74 (11) 74 (11) 
Ethnicity, n (%) 
     Caucasian 
     Non-Caucasian 
  
 
288 (89) 
32 (11) 
 
 
300 (93) 
21 (7) 
SBP mmHg, mean (SD) 149 (23) 150 (22) 
DBP mmHg, mean (SD) 80 (13) 81 (14) 
OCSP, n (%) 
     Total anterior 
     Partial anterior 
 
38 (10) 
149 (40) 
 
34 (9) 
163 (43) 
     Lacunar 
     Posterior 
143 (39) 
42 (11) 
144 (38) 
40 (10) 
Stroke type (Neuroimaging)      
     Acute ischaemic 
     HTI 
     PICH 
     Non relevant* 
     Non-stroke 
 
243 (67) 
5 (1) 
19 (6) 
86 (24) 
8 (2) 
 
211 (58) 
4 (1) 
19 (5) 
121 (33) 
10 (3) 
NIHSS, median (IQR) 4 (3-8) 4 (2-7) 
Premorbid mRS, n (%) 
     0 
     1 
     2 
     3 
 
250 (66) 
71 (19) 
43 (11) 
15 (4) 
 
247 (64) 
66 (17) 
54 (14) 
17 (4) 
Baseline BI, median (IQR) 13 (8-19) 13 (8-19) 
Time since last antihypertensive taken (hour), median (IQR) 19.5 (7.0-29.6) 13.1 (6.7-28.3) 
Time since stroke onset (hour), median (IQR) 23.6 (18.6-35.8) 23.4 (17.5, 34.2) 
Past Medical History, n (%)   
     Stroke 
     TIA 
     Hypertension 
     Diabetes 
     Hypercholesterolaemia 
     IHD 
     Atrial Fibrillation 
     PVD 
63 (17) 
74 (20) 
369 (96) 
69 (22) 
173 (49) 
77 (20) 
72 (19) 
20 (5) 
87 (23) 
66 (17) 
375 (98) 
60 (19) 
177 (49) 
75 (20) 
78 (20) 
22 (6) 
Smoking, n (%) 
     Current 
     Ex-smoker 
 
63 (17) 
145 (39) 
 
57 (15) 
142 (38) 
Alcohol (units/week), median (IQR) 0.5 (0-8) 0 (0-6) 
Family history, n (%) 
     Present 
 
78 (21) 
 
73 (19) 
Baseline number of BP-lowering agents, n (%) 
     1 
     2 
     >3 
 
153 (41) 
135 (36) 
88 (23) 
 
147 (38) 
159 (42) 
77 (20) 
 
Data presented as mean (SD) for symmetrically distributed variables if not stated otherwise. 
Denominators vary due to missing data. OCSP=Oxford Community Stroke Project 
classification. SBP=systolic blood pressure. DBP=diastolic blood pressure. mRS=modified 
Rankin scale. BI=Barthel Index. NIHSS=National Institutes of Health stroke scale. 
IHD=ischaemic heart disease. TIA=transient ischaemic attack. PVD=peripheral vascular 
disease. IQR=interquartile range. *Non relevant=no evidence or acute ischaemic or 
haemorrhagic stroke or non-stroke diagnoses (e.g. non-acute stroke, normal). 
Table 2. Means and differences (95% confidence intervals) in BP, neurological and functional 
parameters between continue and stop arms at 2 weeks (Intention To Treat Population) 
 
 Continue 
(n=379) 
Stop 
(n=384) 
Difference 
(95% CI) 
p-value 
 
SBP (mmHg) 140 (138, 142) 153 (151, 156) 13 (10, 17) <0.001 
DBP (mmHg) 76 (75, 76) 84 (83, 86) 8 (6, 10) <0.001 
NIHSS 3.8 (3.2, 4.3) 3.5 (2.9, 4.0) 0.3 (-0.5, 1.1) 0.46 
BI 15.6 (15.0, 16.2) 16.0 (15.4, 16.6) -0.5 (-1.3, 0.4) 0.30 
Data are mean (95% CI). SBP=systolic blood pressure. DBP=diastolic blood pressure. 
NIHSS=National Institutes of Health Stroke Scale. BI=Barthel Index. 
 
Figure 2: Death or dependency at 2 weeks (Intention To Treat  Population) 
Primary outcome shown as differences in modified Rankin Scale (mRS) between continue 
and stop groups. mRS score of 0=no residual disability; 5=bedbound and requiring 24-hour 
care; 6=death. Figures refer to absolute numbers.  
 
Table 3: Mortality and functional outcomes at 6 months (Intention To Treat Population) 
 Continue 
(n=379) 
Stop 
(n=384) 
Alive 
     Independent (mRS 0) 
     Independent (mRS 1-2) 
     Dependent (mRS 3-5) 
332 (87.6%) 
124 
42 
110 
331 (86.1%) 
118 
53 
112 
Dead 
     Within 2 weeks 
     Between 2 weeks and 6 months 
32 (8.4%) 
 4 
 28 
29 (7.6%) 
 7 
 22 
Missing 15 (4.0%) 24 (6.3%) 
 
Data are numbers (%). mRS=Modified Rankin Scale. Dependency categories were derived 
from the responses to the International Stroke Trial telephone-administered questionnaire 
with an answer yes to the question ‘do you need help from another person for everyday 
activities’ indicating dependency (mRS 3 to 5), and an answer of yes (mRS 0) or no (mRS 1 to 
2) to the question ‘do you feel that you have made a complete recovery from your stroke’ 
indicating independence. 
 
 
Figure 3: Kaplan-Meier survival estimates for continue and stop groups for the 6-month post-
randomisation period (Intention To Treat Population) 
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